In Israel, a biotech startup named ODE Pharma is exploring the therapeutic potential of a molecule discovered in papaya for treating cystic fibrosis (CF) in children. This initiative was inspired by a hypothesis from two esteemed Israeli biochemists, including Nobel laureate Aaron Ciechanover, regarding the molecule's possible health benefits. ODE Pharma has developed a therapy aimed at assisting children afflicted by CF, a genetic disorder characterized by the production of thick mucus in the lungs and other organs, leading to severe respiratory issues and infections.
Current treatment options for CF are limited and costly, but ODE Pharma's approach, utilizing the molecule ODE-001, aims to offer a more accessible and effective solution. The molecule is designed to enhance cellular resilience against inflammation and deterioration. ODE Pharma's CEO, Assaf Bivas, emphasized the goal of transitioning patients from discomfort to comfort, focusing on the well-being of children with CF rather than profit.
The discovery of ODE-001 stemmed from the work of biochemists Shmuel Ben-Sasson and Aaron Ciechanover, who identified the molecule in papaya liquid and speculated on its potential to combat cellular aging. Their insight led to the development of ODE-001 after the Pollen Group, an investment entity co-founded by Bivas, secured the intellectual property rights. Preliminary laboratory tests showed promising results, with ODE-001 extending the lifespan of healthy cells by nearly 50% and demonstrating significant anti-inflammatory effects.
Further validation came from a clinical trial with one of Israel's healthcare providers, yielding positive outcomes. During the COVID-19 pandemic, ODE Pharma also observed encouraging results from administering ODE-001 to severely ill COVID patients, noting a quicker recovery period compared to those who did not receive the treatment. The company has raised $1.5 million in funding and is planning further clinical trials for ODE-001 as a CF treatment, with aspirations for US Food and Drug Administration orphan drug designation. Additionally, ODE Pharma intends to release the molecule as a supplement, collaborating with Catalent for mass production.
Source: NoCamels